Enhanced reputation: Adopting advanced AI-driven technology like Genous™ positions cancer centers as leaders in innovative and personalized care, attracting more patients and skilled professionals.
Improved patient outcomes: Genous™ helps oncologists at cancer centers make more informed treatment decisions, leading to better patient outcomes and increased satisfaction rates.
Streamlined workflow: Genous™ can help automate and optimize molecular diagnostics interpretation and clinical trial matching, allowing cancer centers to operate more efficiently.
Payers (Patients & their families/Insurance)
Cost-effectiveness: By providing personalized treatment recommendations, GenousTM helps payers reduce costs associated with ineffective therapies and trial-and-error approaches.
Better outcomes: Improved treatment success rates translate to reduced long-term healthcare costs due to fewer complications and relapses.
Value-based care: GenousTM supports the transition towards value-based care by enabling payers to invest in treatments with a higher likelihood of success for each patient.
Genous™– The benefits of stakeholder
Unlike traditional approaches GenousTM goes beyond simplistic “One-size-fits-all” treatments by leveraging cutting-edge AI technology to analyze each patient’s unique genetic alterations and biomarkers. This approach helps predict responses to multiple targeted therapies with unrivaled accuracy, ensuring that patients receive the most effective treatment tailored to their needs.
GenousTM using the world's first clinically validated universal computational reasoning model for precision oncology. With GenousTM (in general):
Patients can get on the right therapy in days, not months, increasing quality of life and reducing side effects;
Physicians gain access to a comprehensive, data-backed report that serves as a roadmap for personalized cancer treatment for each patient;
Hospitals and health systems make more informed treatment decisions, leading to improved patient outcomes and higher satisfaction rates
